Chang Yunyoung C, Werth Victoria P
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.
Curr Dermatol Rep. 2013 Mar;2(1):48-57. doi: 10.1007/s13671-012-0037-3. Epub 2013 Jan 24.
Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM) are cutaneous autoimmune diseases that have been among the least systematically studied, due in part to the lack of validated outcome instruments in the past. More recent epidemiologic studies have elucidated the incidence and prevalence of these diseases and their subtypes. In addition, the advent of validated clinical outcome measures, including the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), has led to an objective means of measuring activity and damage of the disease. These outcome measures have established the framework for evaluating responsiveness and therapeutic efficacy in clinical trials as well as longitudinal studies to study disease course.
皮肤红斑狼疮（CLE）和皮肌炎（DM）是皮肤自身免疫性疾病，部分由于过去缺乏经过验证的结局评估工具，它们一直是研究最少的系统性疾病。最近的流行病学研究阐明了这些疾病及其亚型的发病率和患病率。此外，包括皮肤红斑狼疮疾病面积和严重程度指数（CLASI）以及皮肤皮肌炎疾病面积和严重程度指数（CDASI）在内的经过验证的临床结局测量方法的出现，为测量疾病的活动度和损伤提供了客观手段。这些结局测量方法为评估临床试验中的反应性和治疗效果以及研究疾病进程的纵向研究建立了框架。
